Abstract
Methylone (2-methylamino-1-[3,4-methylenedioxyphenyl]propane-1-one) is a synthetic hallucinogenic amphetamine analog, like MDMA (3,4-methylenedioxy- methamphetamine), considered to act on monoaminergic systems. However, the psychopharmacological profile of its cytotoxicity as a consequence of monoaminergic deficits remains unclear. We examined here the effects of methylone on the transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT), using a heterologous expression system in CHO cells, in association with its cytotoxicity. Methylone inhibited the activities of DAT, NET, and SERT, but not GABA transporter-1 (GAT1), in a concentrationdependent fashion with a rank order of NET > DAT > SERT. Methylone was less effective at inhibiting DAT and NET, but more effective against SERT, than was methamphetamine. Methylone alone was not toxic to cells except at high concentrations, but in combination with methamphetamine had a synergistic effect in CHO cells expressing the monoamine transporters but not in control CHO cells or cells expressing GAT1. The ability of methylone to inhibit monoamine transporter function, probably by acting as a transportable substrate, underlies the synergistic effect of methylone and methamphetamine.
Keywords: Methylone, neurotransmitter transporter, uptake, cocaine, methamphetamine, MDMA, Cytotoxicity, monoaminergic Systems, CHO cells, Dopamine (DAT), norpinephrine (NET)
Current Neuropharmacology
Title: Methylone and Monoamine Transporters: Correlation with Toxicity
Volume: 9 Issue: 1
Author(s): Chiharu Sogawa, Norio Sogawa, Kazumi Ohyama, Ruri Kikura-Hanajiri, Yukihiro Goda, Ichiro Sora and Shigeo Kitayama
Affiliation:
Keywords: Methylone, neurotransmitter transporter, uptake, cocaine, methamphetamine, MDMA, Cytotoxicity, monoaminergic Systems, CHO cells, Dopamine (DAT), norpinephrine (NET)
Abstract: Methylone (2-methylamino-1-[3,4-methylenedioxyphenyl]propane-1-one) is a synthetic hallucinogenic amphetamine analog, like MDMA (3,4-methylenedioxy- methamphetamine), considered to act on monoaminergic systems. However, the psychopharmacological profile of its cytotoxicity as a consequence of monoaminergic deficits remains unclear. We examined here the effects of methylone on the transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT), using a heterologous expression system in CHO cells, in association with its cytotoxicity. Methylone inhibited the activities of DAT, NET, and SERT, but not GABA transporter-1 (GAT1), in a concentrationdependent fashion with a rank order of NET > DAT > SERT. Methylone was less effective at inhibiting DAT and NET, but more effective against SERT, than was methamphetamine. Methylone alone was not toxic to cells except at high concentrations, but in combination with methamphetamine had a synergistic effect in CHO cells expressing the monoamine transporters but not in control CHO cells or cells expressing GAT1. The ability of methylone to inhibit monoamine transporter function, probably by acting as a transportable substrate, underlies the synergistic effect of methylone and methamphetamine.
Export Options
About this article
Cite this article as:
Sogawa Chiharu, Sogawa Norio, Ohyama Kazumi, Kikura-Hanajiri Ruri, Goda Yukihiro, Sora Ichiro and Kitayama Shigeo, Methylone and Monoamine Transporters: Correlation with Toxicity, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017425
DOI https://dx.doi.org/10.2174/157015911795017425 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Antitumorigenic Effect of Memantine via Interfering Glutamate Metabolism in Mouse 4T1 Breast Tumor Model
Anti-Cancer Agents in Medicinal Chemistry The Physiological Relevance of Protein Phosphatase 1 and its Interacting Proteins to Health and Disease
Current Medicinal Chemistry Functional Effects of Levosimendan in Rat Basilar Arteries In Vitro
Current Neurovascular Research Heart Rate Lowering by Inhibition of the Pacemaker Current: A New Therapeutic Perspective in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks
Current Alzheimer Research Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Regulation of Glycolytic and Mitochondrial Metabolism by Ras
Current Pharmaceutical Biotechnology Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II
Current Neuropharmacology Melatonin Attenuates Methamphetamine-Induced Neurotoxicity
Current Pharmaceutical Design Target-directed Discovery and Bioprocess Engineering of New Enzymes for Environmentally Benign Production of High-Value Chiral Chemicals
Current Organic Chemistry Recent Applications of Replica-Exchange Molecular Dynamics Simulations of Biomolecules
Current Physical Chemistry Method Validation for the Determination of Carbamazepine in Spiked-saliva Using HPLC-UV for Therapeutic Drug Monitoring Application
Current Psychopharmacology Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Are Cerebrovascular White Matter Lesions an Early Sign of Vascular Cognitive Impairment and Vascular Dementia?
Vascular Disease Prevention (Discontinued) Atypical antipsychotics and inverse agonism at 5-HT<sub>2</sub> receptors
Current Pharmaceutical Design Functionalization of the Carbonyl Group in Position 6 of Morphinan-6-ones. Development of Novel 6-Amino and 6-Guanidino Substituted 14-Alkoxymorphinans
Current Pharmaceutical Design Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Characterisation of a Neural Teratogenicity Assay Based on Human ESCs Differentiation Following Exposure to Valproic Acid
Current Medicinal Chemistry Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis
Current Neuropharmacology